BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. The meeting will take place at the Walter E. Washington Convention Center in Washington, D.C., from February 23-26, 2024.
Related news for (BCRX)
- BioCryst Buys Growth, STRATA Shines in Rare Cancer, and Spider Silk Soars
- Breaking News: MoBot’s Latest Update as of 05/05/25 03:00 PM
- Today’s Top Performers: MoBot’s Market Review 05/05/25 02:00 PM
- BioCryst Pharmaceuticals Soars with Stellar Q1 2025 Results, Raises ORLADEYO Guidance, and Achieves Profitability Ahead of Schedule
- BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update